CJC-1295 isn't available on pharmacy shelves in Rösa or virtually any local market — it's a research compound distributed through a dedicated online market. The practical takeaway for Rösa researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is identical for researchers everywhere. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. This guide walks Rösa researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Rösa researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The most effective path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums aggregate real purchasing experience that are more accurate than commercial vendor claims. The HPLC purity trace is the most important document in the COA: it should show a large primary peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. The combination of community reputation data and your own COA analysis is the most effective quality filter — community feedback surfaces systemic problems invisible in one transaction, and vice versa. The dry lyophilised powder of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations degrade within weeks even when refrigerated.
Order CJC-1295 — ships to Rösa
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without any obvious sign; always maintain cold chain and work with cold-shipped material. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results stated as EU/mg and verify they are within the acceptable range for your research context. PubMed and related preprint servers provide the most complete literature coverage for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
